Testing a Two-Pronged attack on breast cancer before surgery
NCT ID NCT01750073
Summary
This study tested a treatment plan for people with early-stage breast cancer who had not yet had surgery. The goal was to see if giving strong chemotherapy before surgery, with or without the drug trastuzumab (Herceptin), could shrink tumors effectively and be well-tolerated. Researchers wanted to see if this approach led to no detectable cancer in the tissue removed during surgery and to understand the side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHI Health Saint Francis
Grand Island, Nebraska, 68803, United States
-
Nebraska Medicine-Bellevue
Bellevue, Nebraska, 68123, United States
-
Nebraska Medicine-Village Pointe Cancer Center
Omaha, Nebraska, 68118, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.